Bicara Therapeutics Inc. Common Stock (BCAX) Stock Forecast & Price Target
Bicara Therapeutics Inc. Common Stock · NASDAQ
$26.87-0.94 (-3.38%)
15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 11 firms covering Bicara Therapeutics Inc. Common Stock, 8 rate it Buy or better, 3 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets range widely, $16.00 to $42.00 (about 2.6x), a sign of real disagreement on valuation. The average target of $30.27 sits 13% above the current $26.87. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 6 to 8 over recent months. On the fundamentals, the Street sees revenue growth near 0% this year and 0% next, consensus EPS building from about $-0.85 next quarter toward $-3.63 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS11 ratings
Moderate Buy
Strong Buy00%
Buy873%
Hold327%
Sell00%
Strong Sell00%
Based on 11 analysts giving stock ratings to Bicara Therapeutics Inc. Common Stock.
As of Jul, 8 of 11 firms rate BCAX a Buy (3 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
BCAX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.85
Range $-1.02 – $-0.51 · 13 analysts · +27% YoY
Next period, 13 analysts expect Bicara Therapeutics Inc. Common Stock to earn $-0.85 a share (range $-1.02 – $-0.51), versus $-0.67 a year earlier. Full-year consensus is $-3.48, growing to $-3.63 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 13 analysts · +0% YoY
Revenue is expected to reach $0 (range $0 – $0), +0.0% year-over-year. Full-year consensus is $0, rising to $0 next year.
Top analysts covering Bicara Therapeutics Inc. Common Stock
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on BCAX.
#1
David Nierengarten
Wedbush · Rank #115
Buy
$30.00+11.6% to target
Overall win rate
41%
+ Follow
#2
RB
Robert Burns
HC Wainwright & Co. · Rank #195
Buy
$42.00+56.3% to target
Overall win rate
38%
+ Follow
#3
TA
Tazeen Ahmad
B of A Securities · Rank #275
Buy
$35.00+30.3% to target
Overall win rate
41%
+ Follow
#4
Reni J. Benjamin
JMP Securities · Rank #290
Buy
$31.00+15.4% to target
Overall win rate
33%
+ Follow
#5
EF
Eva Fortea Verdejo
Wells Fargo
Hold
$16.00-40.5% to target
Coverage
—
+ Follow
BCAX stock forecast FAQ
What is BCAX's average 12-month price target?+
The 11 analysts with a live target average $30.27 for Bicara Therapeutics Inc. Common Stock over the next 12 months, ranging from a $42.00 high to a $16.00 low.
Is BCAX stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 11 analyst ratings, 8 are Buy or Strong Buy, 3 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for BCAX?+
The Street-high target is $42.00 (Guggenheim), and the Street-low is $16.00 (Wells Fargo). The average of all 11 active targets is $30.27.
How many Wall Street analysts cover BCAX?+
11 analysts have an active rating on Bicara Therapeutics Inc. Common Stock, and 11 firms carry a live 12-month price target.
Who is the most accurate analyst covering BCAX?+
Among analysts who currently cover BCAX, David Nierengarten of Wedbush has the strongest overall Quantellect track record (Rank #115). Their current call is Buy with a $30.00 target.
What is Bicara Therapeutics Inc. Common Stock's projected EPS for next quarter?+
The consensus estimate is $-0.85 per share (range $-1.02 – $-0.51) across 13 analysts. Full-year EPS is projected at $-3.48, rising to $-3.63 the following year.
How much revenue is Bicara Therapeutics Inc. Common Stock expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading BCAX lately?+
As of Jul, 8 of 11 firms rate BCAX a Buy (3 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their BCAX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
